Surrozen, Inc./DE

CHFW, Consonance-HFW Acquisition Corp, was a blank-check company that completed its initial public offering in 2020, targeting opportunities in the healthcare and biopharmaceutical sector. Sponsored by Consonance Capital Management, a healthcare-focused investment firm, the SPAC announced a business combination with Surrozen, Inc., a clinical-stage biopharmaceutical company developing Wnt pathway-targeted therapeutics for tissue repair and organ regeneration. The 10-Q filing dated May 24, 2021, filed under accession number 0001193125-21-169878, reflects the company's SEC reporting obligations during its deSPAC transition period. Surrozen subsequently traded on Nasdaq under a new ticker following the merger closing. Sign up at SpacDesk for full filing history, deal timelines, and comparable SPAC transaction data.